- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Amgen taps Stanford's Howard Chang to take CSO reins from Jay Bradner | ||
| Mi | Viking pads case for MASH drug with final ph. 2 data showing significant reductions in liver fibrosis | ||
| Mi | Plant compound genipin restores nerves, physical sensation in mice with familial dysautonomia | ||
| Mi | Novartis taps Vyriad's viral vectors to develop in vivo T cell editing | ||
| Mi | Medtronic scores FDA clearance for smart insulin pen app aimed at multiple daily injections | ||
| Mi | Pfizer plucks internal candidate to replace R&D head Dolsten, triggering series of leadership shakeups | ||
| Mi | NewAmsterdam's cholesterol drug scores another phase 3 win-and disappoints investors again | ||
| Mi | Biotechs go big for bitcoin: Trio of companies each plan to stash $1M as reserve | ||
| Mi | Sage drops dalzanemdor as Huntington's failure completes clean sweep of midphase flops | ||
| Mi | Pfizer, Flagship return to obesity as part of latest additions to multibillion-dollar collaboration | ||
| Mi | Amid broader uncertainty, biopharma market may have reached 'new norm': PitchBook | ||
| Di | CRO Lindus Health launches latest 'all-in-one' service for infectious disease clinical trials | ||
| Di | Medtronic sees pulsed field ablation cut into cryo sales, amid supply issues | ||
| Di | Jupiter takes off with $70M fund for cancer biotechs | ||
| Di | AHA 2024: Boston Scientific, Abbott tout long-term heart occluder data | ||
| Di | J&J, Protagonist's oral psoriasis prospect scores in phase 3 pair, readying case against BMS' Sotyktu | ||
| Di | 'Some call it the J.P. Morgan of Europe': Jefferies' London conference goes big for 2024 | ||
| Di | Canadian CRO Innovaderm looks to expand in Europe with new vice president | ||
| Di | Lilly's lipoprotein-blocking heart med posts midstage win, turning up heat on potential AstraZeneca showdown | ||
| Di | GSK scratches itch for phase 3 win, hitting goal in liver disease trial to open up untapped market | ||
| Di | AI data platform builder Citizen Health raises $14.5M, inks CZI partnership on rare disease | ||
| Di | Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news | ||
| Di | Incyte's $750M buyout rocked by pause on key trial, asset cull | ||
| Mo | Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis | ||
| Mo | After seeing improved muscle function in phase 1/2 trial, Regenxbio launches pivotal DMD study |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
